FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W3120703389> ?p ?o ?g. }

• W3120703389 endingPage "S789" @default.
• W3120703389 startingPage "S789" @default.
• W3120703389 abstract "Abstract Background Relebactam (REL) is an inhibitor of class A and C β-lactamases approved in the USA in combination with imipenem (IMI) and cilastatin for the treatment of complicated intraabdominal and urinary tract infections. Elevated antimicrobial resistance rates have been reported in ICUs. Using isolates collected in Asia/Pacific for the SMART surveillance program, we evaluated the activity of IMI/REL and comparators against K. pneumoniae (KP) and P. aeruginosa (PA) from ICU patients. Methods In 2015-2018, 51 clinical laboratories in Australia, Hong Kong, Malaysia, New Zealand, Philippines, Singapore, South Korea, Taiwan, Thailand, and Vietnam each collected up to 250 consecutive aerobic gram-negative pathogens per year. Susceptibility was determined using CLSI broth microdilution and CLSI and FDA (IMI/REL) breakpoints. IMI-nonsusceptible KP and PA were screened for β-lactamase genes. Results Analyzing only the 6322 isolates from ICU patients, the 3 most common species collected were KP (21.4%), E. coli (20.5%), and PA (19.7%). Tables 1 and 2 show % susceptible and % MBL- and/or OXA-48-like-positive for the most common Enterobacterales species (KP; 70.6% from lower respiratory tract, 17.6% from intraabdominal, 7.1% from urinary tract, and 4.1% from bloodstream infections) and the most common non-Enterobacterales species (PA; 83.6%, 9.9%, 4.3%, and 1.9%, respectively). % IMI/REL-susceptible ranged from 66-79% in Thailand and Vietnam (where 13-36% of isolates carried MBL and/or OXA-48-like carbapenemases, which REL does not inhibit) to ≥95% in 6 countries (0-3% MBL- and/or OXA-48-like-positive). Among 103 IMI/REL-nonsusceptible KP isolates, 66.0% carried MBL, 20.4% OXA-48-like carbapenemases, 2.9% KPC, 2.9% acquired AmpC and/or ESBL, and in 7.8% no acquired β-lactamases were detected. Among 145 IMI/REL- nonsusceptible PA, 54.5% carried MBL, 1.4% GES carbapenemases, 4.1% only ESBL, and 40.0% no acquired β-lactamases. Table 1. Antimicrobial susceptibility of K. pneumoniae collected from ICU patients Table 2. Antimicrobial susceptibility of P. aeruginosa collected from ICU patients Conclusion IMI/REL was active against 92% of KP and 88% of PA from ICU patients in Asia/Pacific overall, with higher activity in countries with lower prevalence of MBL or OXA-48-like carbapenemases. IMI/REL provides a potential treatment option for ICU patients in Asia/Pacific with infections caused by KP and PA. Disclosures Sibylle Lob, PhD, IHMA (Employee)Pfizer, Inc. (Consultant) Wei-Ting Chen, MD, Merck, Sharp & Dohme, Taiwan (Employee) Yivonne Khoo, PhD, Merck, Sharp & Dohme, Malaysia (Employee) Kanchan Balwani, MBBS, MS, Merck, Sharp & Dohme, Hong Kong (Employee) Katherine Young, MS, Merck & Co., Inc. (Employee, Shareholder)Merck & Co., Inc. (Employee, Shareholder) Mary Motyl, PhD, Merck & Co, Inc (Employee, Shareholder) Daniel F. Sahm, PhD, IHMA (Employee)Pfizer, Inc. (Consultant)Shionogi & Co., Ltd. (Independent Contractor)" @default.
• W3120703389 created "2021-01-18" @default.
• W3120703389 creator A5008370890 @default.
• W3120703389 creator A5017159626 @default.
• W3120703389 creator A5038009031 @default.
• W3120703389 creator A5042149117 @default.
• W3120703389 creator A5042818728 @default.
• W3120703389 creator A5048325629 @default.
• W3120703389 creator A5062847775 @default.
• W3120703389 creator A5089366807 @default.
• W3120703389 date "2020-10-01" @default.
• W3120703389 modified "2023-10-15" @default.
• W3120703389 title "1583. In Vitro Activity of Imipenem/Relebactam against Klebsiella pneumoniae and Pseudomonas aeruginosa from Patients in ICUs in the Asia/Pacific region – SMART 2015-2018" @default.
• W3120703389 doi "https://doi.org/10.1093/ofid/ofaa439.1763" @default.
• W3120703389 hasPublicationYear "2020" @default.
• W3120703389 type Work @default.
• W3120703389 sameAs 3120703389 @default.
• W3120703389 citedByCount "1" @default.
• W3120703389 countsByYear W31207033892022 @default.
• W3120703389 crossrefType "journal-article" @default.
• W3120703389 hasAuthorship W3120703389A5008370890 @default.
• W3120703389 hasAuthorship W3120703389A5017159626 @default.
• W3120703389 hasAuthorship W3120703389A5038009031 @default.
• W3120703389 hasAuthorship W3120703389A5042149117 @default.
• W3120703389 hasAuthorship W3120703389A5042818728 @default.
• W3120703389 hasAuthorship W3120703389A5048325629 @default.
• W3120703389 hasAuthorship W3120703389A5062847775 @default.
• W3120703389 hasAuthorship W3120703389A5089366807 @default.
• W3120703389 hasBestOaLocation W31207033891 @default.
• W3120703389 hasConcept C104317684 @default.
• W3120703389 hasConcept C126322002 @default.
• W3120703389 hasConcept C176947019 @default.
• W3120703389 hasConcept C2776012195 @default.
• W3120703389 hasConcept C2777058267 @default.
• W3120703389 hasConcept C2777637488 @default.
• W3120703389 hasConcept C2779631663 @default.
• W3120703389 hasConcept C2780950330 @default.
• W3120703389 hasConcept C4937899 @default.
• W3120703389 hasConcept C501593827 @default.
• W3120703389 hasConcept C523546767 @default.
• W3120703389 hasConcept C534529494 @default.
• W3120703389 hasConcept C54355233 @default.
• W3120703389 hasConcept C547475151 @default.
• W3120703389 hasConcept C55493867 @default.
• W3120703389 hasConcept C71924100 @default.
• W3120703389 hasConcept C86803240 @default.
• W3120703389 hasConcept C89423630 @default.
• W3120703389 hasConcept C94665300 @default.
• W3120703389 hasConceptScore W3120703389C104317684 @default.
• W3120703389 hasConceptScore W3120703389C126322002 @default.
• W3120703389 hasConceptScore W3120703389C176947019 @default.
• W3120703389 hasConceptScore W3120703389C2776012195 @default.
• W3120703389 hasConceptScore W3120703389C2777058267 @default.
• W3120703389 hasConceptScore W3120703389C2777637488 @default.
• W3120703389 hasConceptScore W3120703389C2779631663 @default.
• W3120703389 hasConceptScore W3120703389C2780950330 @default.
• W3120703389 hasConceptScore W3120703389C4937899 @default.
• W3120703389 hasConceptScore W3120703389C501593827 @default.
• W3120703389 hasConceptScore W3120703389C523546767 @default.
• W3120703389 hasConceptScore W3120703389C534529494 @default.
• W3120703389 hasConceptScore W3120703389C54355233 @default.
• W3120703389 hasConceptScore W3120703389C547475151 @default.
• W3120703389 hasConceptScore W3120703389C55493867 @default.
• W3120703389 hasConceptScore W3120703389C71924100 @default.
• W3120703389 hasConceptScore W3120703389C86803240 @default.
• W3120703389 hasConceptScore W3120703389C89423630 @default.
• W3120703389 hasConceptScore W3120703389C94665300 @default.
• W3120703389 hasIssue "Supplement_1" @default.
• W3120703389 hasLocation W31207033891 @default.
• W3120703389 hasLocation W31207033892 @default.
• W3120703389 hasLocation W31207033893 @default.
• W3120703389 hasOpenAccess W3120703389 @default.
• W3120703389 hasPrimaryLocation W31207033891 @default.
• W3120703389 hasRelatedWork W1966320936 @default.
• W3120703389 hasRelatedWork W2151828834 @default.
• W3120703389 hasRelatedWork W2162955313 @default.
• W3120703389 hasRelatedWork W2392133069 @default.
• W3120703389 hasRelatedWork W2737410971 @default.
• W3120703389 hasRelatedWork W2948065570 @default.
• W3120703389 hasRelatedWork W3021121956 @default.
• W3120703389 hasRelatedWork W4200081084 @default.
• W3120703389 hasRelatedWork W4318538773 @default.
• W3120703389 hasRelatedWork W4320913353 @default.
• W3120703389 hasVolume "7" @default.
• W3120703389 isParatext "false" @default.
• W3120703389 isRetracted "false" @default.
• W3120703389 magId "3120703389" @default.
• W3120703389 workType "article" @default.